GlaxoSmithKline Pakistan (KAR:GLAXO) Cyclically Adjusted Book per Share: ₨70.94 (As of Mar. 2026)


KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
92 GF Score
Price ₨376.99
GF Value ₨324.20
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pakistan Cyclically Adjusted Book per Share?

GlaxoSmithKline Pakistan KAR:GLAXO +0.23% 92 Cyclically Adjusted Book per Share is ₨70.94 as of Mar. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 92/100 and a GF Value™ of ₨324.20 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

GlaxoSmithKline Pakistan's adjusted book value per share for the three months ended in Mar. 2026 was ₨113.938. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ₨70.94 for the trailing ten years ended in Mar. 2026.

During the past 12 months, GlaxoSmithKline Pakistan's average Cyclically Adjusted Book Growth Rate was 10.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of GlaxoSmithKline Pakistan was 8.10% per year. The lowest was 8.00% per year. And the median was 8.05% per year.

As of today (2026-07-03), GlaxoSmithKline Pakistan's current stock price is ₨376.99. GlaxoSmithKline Pakistan's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was ₨70.94. GlaxoSmithKline Pakistan's Cyclically Adjusted PB Ratio of today is 5.31.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GlaxoSmithKline Pakistan was 6.96. The lowest was 1.24. And the median was 2.68.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GlaxoSmithKline Pakistan's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=376.99/70.94
=5.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of GlaxoSmithKline Pakistan was 6.96. The lowest was 1.24. And the median was 2.68.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


GlaxoSmithKline Pakistan Cyclically Adjusted Book per Share Related Terms


GlaxoSmithKline Pakistan Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Cyclically Adjusted Book per Share Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.29 54.23 57.59 62.20 68.29

GlaxoSmithKline Pakistan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.09 65.76 67.21 68.29 70.94

KAR:GLAXO vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cyclically Adjusted PB Ratio falls into.


KAR:GLAXO
92GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pakistan's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=113.938/330.2130*330.2130
=113.938

Current CPI (Mar. 2026) = 330.2130.

GlaxoSmithKline Pakistan Quarterly Data

Book Value per Share CPI Adj_Book
201606 37.091 241.018 50.817
201609 39.342 241.428 53.810
201612 42.525 241.432 58.163
201703 45.097 243.801 61.081
201706 41.003 244.955 55.274
201709 43.483 246.819 58.175
201712 42.271 246.524 56.621
201803 45.143 249.554 59.734
201806 42.448 251.989 55.625
201809 44.147 252.439 57.748
201812 48.418 251.233 63.639
201903 50.091 254.202 65.069
201906 44.164 256.143 56.935
201909 47.065 256.759 60.529
201912 50.672 256.974 65.114
202003 52.008 258.115 66.535
202006 48.576 257.797 62.221
202009 51.360 260.280 65.160
202012 54.882 260.474 69.576
202103 57.161 264.877 71.261
202106 53.730 271.696 65.302
202109 57.492 274.310 69.209
202112 65.899 278.802 78.051
202203 68.804 287.504 79.025
202206 60.881 296.311 67.847
202209 61.348 296.808 68.253
202212 66.108 296.797 73.551
202303 67.460 301.836 73.802
202306 65.097 305.109 70.453
202309 64.878 307.789 69.605
202312 68.063 306.746 73.270
202403 69.838 312.332 73.836
202406 73.257 314.175 76.997
202409 79.308 315.301 83.059
202412 88.790 315.605 92.900
202503 95.467 319.799 98.576
202506 91.963 322.561 94.145
202509 93.360 324.800 94.916
202512 105.740 324.054 107.750
202603 113.938 330.213 113.938

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of ₨70.94 mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Cyclically Adjusted Book per Share of ₨70.94 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Cyclically Adjusted Book per Share too high?
GlaxoSmithKline Pakistan's current Cyclically Adjusted Book per Share is ₨70.94. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Cyclically Adjusted Book per Share compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Cyclically Adjusted Book per Share of ₨70.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Cyclically Adjusted Book per Share is ₨70.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨324.20, compared to a current price of ₨376.99 — trading 16.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is ₨70.94. GlaxoSmithKline Pakistan's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Cyclically Adjusted Book per Share is ₨70.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be overvalued. The current stock price of ₨376.99 is trading 16.3% above its estimated GF Value™ of ₨324.20. GuruFocus considers GlaxoSmithKline Pakistan to be Modestly Overvalued.

Key valuation signals for KAR:GLAXO:

  • Cyclically Adjusted Book per Share: ₨70.94
  • GF Value™: ₨324.20 vs. price of ₨376.99 (16.3% above fair value)
  • GF Score™: 92/100 with 1 warning sign

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
92GF Score

Get the complete analysis for KAR:GLAXO

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨376.99
Price
₨324.20
GF Value